

1 **BRIEF REPORT: Impact of age and SARS-CoV-2 breakthrough infection on humoral immune**  
2 **responses after three doses of COVID-19 mRNA vaccine**

3

4 Francis Mwimanzi<sup>1</sup>, Hope R. Lapointe<sup>2</sup>, Peter K. Cheung<sup>1,2</sup>, Yurou Sang<sup>1</sup>, Fatima Yaseen<sup>1</sup>, Rebecca  
5 Kalikawe<sup>1</sup>, Sneha Datwani<sup>1</sup>, Laura Burns<sup>3</sup>, Landon Young<sup>3</sup>, Victor Leung<sup>4,5</sup>, Siobhan Ennis<sup>1</sup>, Chanson  
6 J. Brumme<sup>2,4</sup>, Julio S.G. Montaner<sup>2,4</sup>, Natalie Prystajecy<sup>5,6</sup>, Christopher F. Lowe<sup>3,5</sup>, Mari L.  
7 DeMarco<sup>3,5</sup>, Daniel T. Holmes<sup>3,5</sup>, Janet Simons<sup>3,5</sup>, Masahiro Niikura<sup>1</sup>, Marc G. Romney<sup>3,5,\*</sup>, Zabrina L.  
8 Brumme<sup>1,2,\*</sup>, Mark A. Brockman<sup>1,2,\*</sup>

- 9  
10 1. Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6, Canada;  
11 2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, V6Z 1Y6, Canada;  
12 3. Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, V6Z 1Y6, Canada;  
13 4. Department of Medicine, University of British Columbia, Vancouver, V6T 1Z3, Canada;  
14 5. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,  
15 V6T 1Z7, Canada  
16 6. British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, V5Z 4R4,  
17 Canada

18  
19 \*MAB, MGR and ZLB contributed equally

20  
21 **Corresponding Author Contact Information:**

22 Mark A. Brockman, Ph.D.  
23 Professor, Faculty of Health Sciences, Simon Fraser University  
24 8888 University Drive, Burnaby, BC, Canada, V5A 1S6  
25 Tel: 778 782-3341; Fax: 778-782-5927;  
26 email: [mark\\_brockman@sfu.ca](mailto:mark_brockman@sfu.ca)

27

28

29 **ABSTRACT**

30 Longitudinal immune response data following three-dose COVID-19 mRNA vaccination remain  
31 limited, particularly in older adults and those experiencing their first SARS-CoV-2 infection. We  
32 quantified wild-type- and Omicron-specific antibody concentrations and virus neutralization activity up  
33 to six months post-third-dose in COVID-19-naïve adults aged 24-98 years. Among participants who  
34 remained COVID-19-naïve, antibody concentrations were comparable between age groups over time.  
35 Omicron-specific neutralization declined more rapidly in older adults, and at six months was  
36 undetectable in 56% and 96% of COVID-19-naïve younger and older adults, respectively. Post-vaccine  
37 SARS-CoV-2 breakthrough infections increased wild-type- and Omicron-specific responses above  
38 three-dose vaccination alone, illustrating beneficial hybrid immunity.

39

40 **Key words:** COVID-19, mRNA vaccine, humoral immunity, hybrid immunity, post-vaccination  
41 infection, older adults, binding antibodies, viral neutralization, Omicron

## 42 INTRODUCTION

43 Third COVID-19 mRNA vaccine doses, provided to immunocompromised and clinically-  
44 vulnerable individuals to complete their initial vaccine series [1-3] or as "booster" doses in the general  
45 population to offset natural antibody decline and augment responses against the more immune-evasive  
46 Omicron variants [4], enhanced protection against severe disease [1, 5, 6] but did not prevent  
47 widespread Omicron-driven infections [7, 8]. Few studies have assessed post-third-dose immune  
48 response durability across the adult age spectrum, nor compared vaccine-induced to "hybrid" antibody  
49 responses elicited by three-dose vaccination followed by SARS-CoV-2 breakthrough infection,  
50 information that could help inform the design and delivery of future vaccine boosters.

51 In a prior study, we reported that older adults mounted weaker antibody responses than  
52 younger adults after two vaccine doses, but equivalent initial responses after three doses [9]. Here, we  
53 longitudinally examine wild-type- and Omicron-specific antibody concentration and function up to six  
54 months post-third-dose in 116 individuals who remained COVID-19-naïve until at least one month  
55 post-third-dose. One-third of participants experienced SARS-CoV-2 (presumably Omicron) infection  
56 during follow-up, allowing us to additionally compare vaccine-induced and "hybrid" immune responses  
57 [10].

58

## 59 METHODS

60 **Participants.** Our British Columbia (BC), Canada, cohort has been described previously [9]. Here, we  
61 studied the subset of 69 healthcare workers (HCW) and 47 older adults (OA) who remained COVID-19  
62 naive until at least one month after their third COVID-19 mRNA vaccine dose (**Table S1**). Post-  
63 vaccine SARS-CoV-2 infections were detected by the development of serum antibodies against

64 Nucleocapsid (N) using the Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics), combined with  
65 diagnostic (PCR- and/or rapid-antigen-test-based) information.

66

67 **Ethics approval.** Written informed consent was obtained from all participants or their authorized  
68 decision makers. This study was approved by the University of British Columbia/Providence Health  
69 Care and Simon Fraser University Research Ethics Boards.

70

71 **Assays.** We quantified IgG-binding antibodies in serum against the SARS-CoV-2 Spike Receptor  
72 Binding Domain (RBD) using the V-plex SARS-CoV-2 (IgG) ELISA kit (Panel 22; Meso Scale  
73 Diagnostics), which features WT (Wuhan) and Omicron (BA.1) RBD antigens, on a Meso QuickPlex  
74 SQ120 instrument. Serum was diluted 1:10000, with results reported in Arbitrary Units (U)/mL. We  
75 assessed surrogate virus neutralization activity [11] in serum by competition ELISA using the same kit  
76 (Panel 22; V-plex SARS-CoV-2 [ACE2]) to measure blockade of the RBD-ACE2 receptor interaction.  
77 Sera were diluted 1:40 and results reported as % ACE2 displacement. A subset of specimens was also  
78 tested for IgG-binding antibodies and ACE2 displacement using V-plex assays that featured Wuhan,  
79 BA.1, BA.2 and BA.3 Spike antigens (Panel 25). Virus neutralizing activity in plasma was examined  
80 using live WT (USA-WA1/2020; BEI Resources) and Omicron BA.1 (GISAID EPI\_ISL\_9805779)  
81 viruses on VeroE6-TMPRSS2 (JCRB-1819) target cells [9]. Virus stocks were diluted to 50  
82 TCID<sub>50</sub>/200 µl in the presence of serial 2-fold plasma dilutions (1/20 to 1/2560) and added to target  
83 cells in triplicate. Viral cytopathic effects (CPE) were recorded three days post-infection.  
84 Neutralization was reported as the highest reciprocal dilution able to prevent CPE in all three wells.  
85 Partial or no neutralization at 1/20 dilution was considered below the limit of quantification (BLOQ).

86

## 87 **RESULTS**

### 88 *Participant characteristics*

89 HCW and OA were a median of 40 and 78 years old, respectively (range 24-98 years old), and  
90 predominantly female (**Table S1**). OA were predominantly of white ethnicity (74%, compared to 46%  
91 of HCW) and had more chronic health conditions (median of 1, interquartile range [IQR] 0-2 in OA  
92 versus 0 [IQR 0-1] in HCW). Most participants (97% of HCW and 81% of OA) initially received two  
93 BNT162b2 doses. Third doses were predominantly mRNA-1273 (52% of HCW and 62% of OA),  
94 which were administered in an age-dependent manner per local guidelines: most OA received 100 mcg  
95 whereas HCW received 50 mcg. Third doses were administered an average of ~7 months after the  
96 second. During follow-up, 43% of HCW and 17% of OA experienced their first SARS-CoV-2  
97 infection; based on local epidemiology most were suspected to be Omicron BA.1 or BA.2 [12].

98

### 99 *Binding antibodies*

100 As reported previously [9, 13], anti-RBD serum IgG concentrations were lower in COVID-19-  
101 naive OA compared to younger HCW after two vaccine doses, but the third dose significantly enhanced  
102 these responses (**Figure 1A**). One month post-third dose, WT-specific anti-RBD IgG concentrations  
103 were equivalent in the two groups: a median of 5.21 (IQR 5.08-5.45)  $\log_{10}$  U/mL in HCW versus 5.25  
104 (IQR 4.99-5.43) in OA ( $p=0.7$ ). Among COVID-19-naive participants, WT-specific IgG responses  
105 declined to a median 4.95 (IQR 4.79-5.16) in HCW versus 4.96 (IQR 4.76-5.17) in OA at three months  
106 post-third dose ( $p=0.9$ ), and to a median 4.64 (IQR 4.42-4.84) in HCW versus 4.59 (IQR 4.35-4.87) in  
107 OA by six months ( $p=0.7$ ). By six months, IgG concentrations in COVID-19-naive HCW had declined  
108 to below post-second-dose levels ( $p<0.0001$ ) while in OA they had declined to comparable levels as  
109 achieved by two doses ( $p=0.2$ ). Following three doses, the half-life of WT-specific IgG was estimated

110 to be a median 73 (IQR 53-101) days in COVID-19-naive HCW versus 69 (IQR 54-91) days in OA  
111 (p=0.8; **Figures 1B, 1C**).

112 By contrast, individuals who experienced SARS-CoV-2 infection during follow-up exhibited  
113 markedly higher IgG concentrations than their COVID-19-naive counterparts at three and six months  
114 post-third dose (both p<0.0001; **Figure 1A**). Notably, at six months, IgG concentrations in "hybrid  
115 immunity" participants were a median 5.50 (IQR 5.17-5.79) log<sub>10</sub> U/mL, which was significantly  
116 higher than their responses induced by three vaccine doses alone (p=0.0005). Individual-level  
117 longitudinal responses are detailed in **Figure S1**. Identical trends were observed for Omicron (BA.1)-  
118 specific IgG concentrations, though these were on average ~0.6 log<sub>10</sub> lower than WT-specific responses  
119 at all time points (**Figure 1A; Figure S1**). In COVID-19-naive individuals, Omicron-specific IgG half-  
120 lives were similar to WT-specific ones and were comparable between OA (median 75 days [IQR 58-  
121 93]) and HCW (78 [IQR 64-94]) (p=0.5; **Figure S2**).

122

### 123 *ACE2 displacement*

124 While ACE2 displacement activities against WT and Omicron (BA.1) variants were lower in  
125 COVID-19-naive OA compared to HCW following two vaccine doses, these responses increased to  
126 equivalence one month post-third dose: a median 98.7% (IQR 96.3-99.3) in HCW versus 99.3% (IQR  
127 96.0-99.7) OA for WT (p=0.12), and a median of 62.5% (IQR 46.2-75.5) in HCW versus 66.2% (IQR  
128 44.6-79.3) in OA for Omicron BA.1 (p=0.4) (**Figure 2A**). Among COVID-19-naive participants, WT-  
129 specific ACE2 displacement activities declined similarly in both groups, to a median 98.0% (IQR 93.7-  
130 99.3) in HCW versus 98.3% (IQR 91.7-99.5) in OA at three months post-third dose (p=0.9), and a  
131 median 92.8% (IQR 80.0-99.9) in HCW versus 91.4% (IQR 72.3-97.1) in OA at six months (p=0.4).  
132 Omicron-specific ACE2 displacement declined slightly faster in OA, particularly between 3-6 months,

133 to a median 48.6% (IQR 20.5-73.8) in HCW versus 47.6% (IQR 14.2-71.7) in OA at three months  
134 post-third dose ( $p=0.4$ ), and a median 43.3% (IQR 13.4-62.2) in HCW versus 20.7% (IQR 5.6-32.3) in  
135 OA at six months ( $p=0.04$ ). By six months post-third dose, WT- and Omicron-specific ACE2  
136 displacement activities in COVID-19-naive HCW had declined to below post-second-dose levels  
137 ( $p<0.0001$  and  $p=0.02$  respectively), while in COVID-19-naive OA they had declined to comparable  
138 levels as achieved after two doses ( $p=0.6$  and  $p=0.4$ , respectively). By contrast, post-vaccination  
139 SARS-CoV-2 infection induced a strong functional boost: at six months, ACE2 displacement activities  
140 against both WT and Omicron in the hybrid immunity group significantly exceeded those originally  
141 induced by three vaccine doses alone (both comparisons  $p<0.0001$ ; **Figure 2A**; also see **Figure S1**).  
142 Omicron-specific ACE2 displacement activities for example rose to a median 95.9% (IQR 90.0-97.8)  
143 in the hybrid group at six months.

144

#### 145 *Virus neutralization*

146 Live virus neutralization activity was weaker in OA versus younger HCW following two  
147 vaccine doses, but it reached equivalence one month post-third-dose when reciprocal plasma dilutions  
148 required to neutralize WT were a median 320 (IQR 160-320) in HCW versus a median 320 (IQR 80-  
149 640) in OA ( $p=0.9$ ), while those required to neutralize Omicron (BA.1) were a median 40 (IQR 20-80)  
150 in both groups ( $p=0.8$ ) (**Figure 2B**). Among COVID-19-naive participants, WT neutralization declined  
151 relatively similarly in both groups, to median reciprocal dilutions of 80 (IQR 80-160) in HCW versus  
152 80 (IQR 40-160) in OA at three months post-third dose ( $p=0.03$ ), and a median 40 (IQR 20-80) in  
153 HCW versus 20 (IQR 20-80) in OA at six months ( $p=0.3$ ). By contrast, Omicron-specific neutralization  
154 declined faster in OA, to median reciprocal dilutions of 40 (IQR 20-80) in HCW versus BLOQ (IQR  
155 BLOQ-BLOQ) in OA at three months ( $p=0.004$ ), and BLOQ (IQR BLOQ-20) in HCW versus BLOQ

156 [IQR BLOQ-BLOQ] in HCW at six months ( $p=0.003$ ). At six months, neutralization function in  
157 COVID-19-naïve participants had declined to below post-second-dose levels (*e.g.* WT-specific  $p$ -  
158 values  $<0.05$ ; **Figure 2B**), and Omicron-specific-neutralization was BLOQ in 56% and 96% of  
159 COVID-19-naïve HCW and OA, respectively. By contrast, post-vaccination SARS-CoV-2 infection  
160 induced a strong neutralization boost: at six months, WT- and Omicron-specific neutralization  
161 activities in the hybrid group significantly exceeded those induced by three vaccine doses alone (all  
162  $p\leq 0.002$ ; **Figure 2B**; also see **Figure S2**). Omicron-specific neutralization for example was a median  
163 reciprocal dilution of 80 (IQR 80-160) in the hybrid group at six months (**Figure 2B**).

164

### 165 *Responses to other Omicron variants*

166 To estimate immune responses to other Omicron variants, we quantified anti-Spike IgG levels  
167 and ACE2 displacement activities specific to WT, BA.1, BA.2 and BA.3 variants in 25 participants one  
168 month post-third-dose. Compared to WT-specific responses, anti-Spike IgG concentrations were on  
169 average  $\sim 0.4 \log_{10}$  lower for Omicron variants, while ACE2 displacement activities were on average at  
170 least 30% lower for Omicron variants (all  $p < 0.0001$ ; **Figure S3**). BA.2-specific anti-Spike IgG  
171 concentrations were comparable to BA.1 ( $p=0.2$ ), while BA.2-specific ACE2 displacement activities  
172 were marginally lower ( $p=0.01$ ). BA.3-specific anti-Spike IgG concentrations and ACE2 displacement  
173 activities were significantly lower than BA.1 (both  $p < 0.0001$ ), though the magnitude of these  
174 differences was modest (*e.g.* median IgG was  $5.42 \log_{10}$  for BA.1 versus  $5.35 \log_{10}$  for BA.3). The  
175 correlation between anti-Spike and anti-RBD measurements for the WT and BA.1 antigens was strong  
176 (Spearman's  $\rho \geq 0.86$ ,  $p < 0.0001$ ; **Figure S3**).

177

178



179 **DISCUSSION**

180 A third COVID-19 mRNA vaccine dose significantly enhances antibody responses in SARS-  
181 CoV-2-naive individuals, including to the Omicron variant, and particularly in older adults. At one,  
182 three and six months post-third-dose, WT- and Omicron-specific anti-RBD binding IgG concentrations  
183 were of comparable magnitude and declined at similar rates in older and younger adults, though  
184 Omicron-specific responses were consistently  $\sim 0.6 \log_{10}$  lower than WT. Longitudinal WT-specific  
185 ACE2 displacement and neutralization activities were also similar between groups, but older adults  
186 displayed lower Omicron-specific ACE2 displacement activity at six months post-third dose, and lower  
187 Omicron-specific neutralization at both three and six months post-third dose compared to younger  
188 adults. This is consistent with impaired Omicron-specific antibody function in older adults that is only  
189 revealed as antibody concentrations decline. Notably, by six months post-third-dose, antibody  
190 responses in COVID-19-naive participants of all ages had declined markedly to or below those initially  
191 elicited by two-dose vaccination, with anti-Omicron neutralization below the limit of quantification in  
192 56% of younger and 96% of older adults by this time (79% of OA were already BLOQ at 3 months).

193 By contrast, both younger and older adults who experienced their first SARS-CoV-2 infection  
194 (presumably Omicron BA.1 or BA.2 [12]) after three-dose vaccination demonstrated superior binding  
195 and functional humoral responses to those induced by triple-vaccination alone. This is consistent with  
196 other studies of hybrid immunity [10, 14, 15] and suggests that a post-third-dose infection may provide  
197 prolonged immune protection. The observation that immune enhancement was most pronounced for  
198 Omicron-specific responses (*e.g.* see Figure 2A), and extended to antibody function, is likely  
199 attributable to exposure to Omicron Spike. If so, heterologous booster vaccination with variant Spike  
200 antigens may offer similar benefits.

201            Though these findings further underscore the immune benefits of third/booster doses in all ages,  
202 they suggest that COVID-19-naive individuals, particularly older adults, may benefit from an  
203 additional booster dose by six months. By contrast, individuals who contracted their first SARS-CoV-2  
204 infection following three-dose vaccination may benefit less from a booster within this time frame.  
205 Exposure to Omicron-like antigens, whether from infection or a multivalent vaccine that includes  
206 variant Spike/RBDs, will likely elicit superior immune responses against circulating variants compared  
207 to immunization with existing, WT-only vaccines. Additional studies are needed to assess the  
208 durability of hybrid immune responses and to evaluate cross-reactivity against emerging viral variants.

209

## 210 **ACKNOWLEDGEMENTS**

211            We thank the leadership and staff of Providence Health Care, including long-term care and  
212 assisted living residences, for their support of this study. We thank the phlebotomists and laboratory  
213 staff at St. Paul's Hospital, the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research  
214 and Innovation Centre, and Simon Fraser University for assistance. Above all, we thank the  
215 participants, without whom this study would not have been possible.

216

## 217 **FUNDING**

218            This work was supported by the Public Health Agency of Canada through a COVID-19  
219 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120 to MGR, ZLB, MAB).  
220 Additional funding was received from the Canadian Institutes for Health Research (GA2-177713 and  
221 the Coronavirus Variants Rapid Response Network (FRN-175622) to MAB), the Canada Foundation  
222 for Innovation through Exceptional Opportunities Fund – COVID-19 awards (to MAB, MD, MN,  
223 ZLB). FM is supported by a fellowship from the CIHR Canadian HIV Trials Network. FY was

224 supported by an SFU Undergraduate Research Award. MLD and ZLB hold Scholar Awards from the  
225 Michael Smith Foundation for Health Research.

226

## 227 **FIGURE LEGENDS**

228 **Figure 1. Serum anti-RBD IgG concentrations following three-dose COVID-19 vaccination.** *Panel*

229 *A:* Longitudinal serum anti-RBD IgG concentrations specific to WT (left side) and Omicron BA.1

230 (right side) in COVID-19-naive health care workers (HCW; blue circles) and older adults (OA; orange

231 circles). Any participant who experienced a SARS-CoV-2 breakthrough infection between 1-3 or 3-6

232 months post-third-dose was reclassified into the "HYBRID" group at their following study visit (black

233 circles). At six months post-third-dose, the black symbols in the HYBRID group denote recent

234 infections occurring between 3-6 months, while the grey symbols denote participants who had been

235 infected between 1-3 months. Red bars indicate median and IQR. Comparisons between independent

236 groups were performed using the Mann-Whitney U-test; longitudinal paired comparisons were

237 performed using the Wilcoxon matched pairs test. P-values are not corrected for multiple comparisons.

238 *Panel B:* Temporal declines in anti-RBD IgG responses following three-dose vaccination in HCW

239 (blue) and OA (orange) who remained COVID-19-naive during follow-up, and who completed all three

240 post-third dose visits. *Panel C:* Estimated IgG half-lives following three-dose vaccination, calculated

241 by fitting an exponential curve to each participant's data in panel B. Red bars and whiskers represent

242 the median and IQR. P-values were computed using the Mann-Whitney U-test.

243

244 **Figure 2. Functional humoral responses following three-dose COVID-19 vaccination.** *Panel A:*

245 Same as Figure 1A, but for ACE2 displacement activity, where results are reported in terms of %

246 ACE2 displacement. *Panel B:* same as Figure 1A, but for virus neutralization activity, defined as the

247 lowest reciprocal plasma dilution at which neutralization was observed in all wells of a triplicate assay.  
248 Serial two-fold dilutions of 1/20 (lower limit of quantification; LLOQ) to 1/2560 (upper limit of  
249 quantification; ULOQ) were tested. Plasma samples showing neutralization in fewer than three wells at  
250 a 1/20 dilution are displayed as a reciprocal dilution of "10" and were reported as below limit of  
251 quantification (BLOQ) in the text. Note that many datapoints are superimposed.

252

### 253 **Supplemental Figures**

254 **Figure S1: Longitudinal humoral responses to WT and Omicron variants following three-dose**  
255 **COVID-19 vaccination.** *Panel A:* Longitudinal serum anti-RBD IgG concentrations specific to WT  
256 (left side) and Omicron BA.1 (right side) in health care workers (HCW; blue circles) and older adults  
257 (OA; orange circles). Blue and orange symbols are jittered for visualization. Participants are stratified  
258 into three groups: COVID-19-naive, SARS-CoV-2 infection between 1-3 months post-third-dose, and  
259 SARS-CoV-2 infection between 3-6 months post-third-dose. P-values are computed using the  
260 Wilcoxon matched pairs test and are not corrected for multiple comparisons. Horizontal red lines  
261 denote the overall median response at each time point (where HCW and OA are treated as a combined  
262 group). *Panel B:* Same as A, but for ACE2 % displacement activity in serum. *Panel C:* Same as A, but  
263 for viral neutralization activity in plasma, defined as the lowest reciprocal plasma dilution at which  
264 neutralization was observed in all triplicate assay wells. Serial two-fold dilutions of 1/20 (lower limit of  
265 quantification; LLOQ) to 1/2560 (upper limit of quantification; ULOQ) were tested. Plasma samples  
266 showing neutralization in fewer than three wells at a 1/20 dilution are displayed as a reciprocal dilution  
267 of "10" and were reported as below limit of quantification (BLOQ) in the text. Note that many  
268 datapoints are superimposed.

269

270 **Figure S2: Omicron-specific anti-RBD IgG decline following three-dose COVID-19 vaccination.**

271 *Panel A:* Temporal declines in Omicron (BA.1)-specific anti-RBD IgG responses following three-dose  
272 vaccination in HCW (blue) and older adults (orange) who remained COVID-19 naive during follow-up,  
273 and who completed all three post-third dose visits. *Panel B:* Estimated Omicron (BA.1)-specific IgG  
274 half-lives following three COVID-19 vaccine doses, calculated by fitting an exponential curve to each  
275 participant's data shown in panel B. Red bars and whiskers represent the median and IQR. P-values  
276 were computed using the Mann-Whitney U-test.

277

278 **Figure S3: Anti-S IgG and ACE2 displacement activities against an expanded panel of Omicron**

279 **variants.** *Panel A:* Concentrations of IgG capable of binding WT, Omicron BA.1, BA.2 and BA.3  
280 Spike proteins in a subset of n=25 participants measured one month post-third vaccine dose. HCW in  
281 blue; OA in orange; dots are jittered for visualization. P-values are computed using the Wilcoxon  
282 matched pairs test and are uncorrected for multiple comparisons. Horizontal red lines denote the overall  
283 median response to each variant (HCW and OA are treated as a combined group). *Panel B:* same as  
284 Panel A, but for ACE2% displacement activity. *Panel C:* Correlation between WT and Omicron BA.1-  
285 specific anti-Spike IgG concentrations (shown in this figure) with the original anti-RBD IgG  
286 measurements shown in the primary analysis (in Figure 1A). *Panel D:* Correlation between WT and  
287 Omicron BA.1-specific anti-Spike ACE2 displacement with the original anti-RBD measurements  
288 shown in the primary analysis.




289

290

291 **REFERENCES**


- 292 1. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-  
293 19 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet* **2021**;  
294 398:2093-100.
- 295 2. Moreira ED, Jr., Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19  
296 Vaccine. *N Engl J Med* **2022**; 386:1910-21.
- 297 3. Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, et al. Antibody Titers Before and After a Third  
298 Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged  $\geq 60$  Years. *JAMA* **2021**;  
299 326:2203-4.
- 300 4. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants  
301 BA.2.12.1, BA.4, & BA.5. *Nature* **2022**.
- 302 5. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA Vaccine Boosters against SARS-  
303 CoV-2 Omicron Infection in Qatar. *N Engl J Med* **2022**; 386:1804-16.
- 304 6. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron  
305 (B.1.1.529) Variant. *N Engl J Med* **2022**; 386:1532-46.
- 306 7. Christensen PA, Olsen RJ, Long SW, et al. Signals of Significantly Increased Vaccine Breakthrough,  
307 Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease  
308 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in  
309 Houston, Texas. *Am J Pathol* **2022**; 192:642-52.
- 310 8. Staerke NB, Reekie J, Nielsen H, et al. Levels of SARS-CoV-2 antibodies among fully vaccinated  
311 individuals with Delta or Omicron variant breakthrough infections. *Nat Commun* **2022**; 13:4466.
- 312 9. Mwimanzi F, Lapointe HR, Cheung PK, et al. Older adults mount less durable humoral responses to  
313 two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose. *J Infect Dis*  
314 **2022**.
- 315 10. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads  
316 to robust humoral response and antibodies that effectively neutralize variants. *Sci Immunol* **2022**;  
317 7:eabn8014.
- 318 11. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on  
319 antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* **2020**;  
320 38:1073-8.
- 321 12. BC Centre for Disease Control. Weekly update on Variants of Concern. Available at:  
322 <http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data>. 2022.
- 323 13. Brockman MA, Mwimanzi F, Lapointe HR, et al. Reduced Magnitude and Durability of Humoral  
324 Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. *J Infect Dis* **2022**;  
325 225:1129-40.

- 326 14. Chen Y, Tong P, Whiteman N, et al. Immune recall improves antibody durability and breadth to  
327 SARS-CoV-2 variants. *Sci Immunol* **2022**:eabp8328.
- 328 15. Curlin ME, Bates TA, Guzman G, et al. Omicron neutralizing antibody response following booster  
329 vaccination compared with breakthrough infection. *medRxiv* **2022**.  
330







**a**




**b**




**a**









**b**



**c**



**a****b**



**Table 1: Participant characteristics**

<b>Characteristic</b>	<b>HCW (n=69)</b>	<b>Older Adults (n=47)</b>
<b>Sociodemographic and health variables</b>		
Age in years, median [IQR]	40 [34-51]	78 [72-83]
Female sex at birth, n (%)	53 (77%)	34 (72%)
white Ethnicity, n (%)	32 (46%)	35 (74%)
Number of chronic health conditions, median [IQR]	0 [0-1]	1 [0-2]
<b>Vaccine details</b>		
Initial regimen		
BNT162b2 - BNT162b2	67 (97%)	38 (81%)
mRNA-1273 - mRNA-1273	1 (1.5%)	7 (15%)
heterologous mRNA	1 (1.5%)	2 (4%)
Third dose		
BNT162b2	33 (48%)	18 (38%)
mRNA-1273	36 (52%)	29 (62%)
Date range that third doses were received	Oct 2021-Feb 2022	Oct 2021-Jan 2022
Time between second and third doses in days, median [IQR]	210 [199-232]	198 [173-216]
<b>Specimen collection</b>		
1 month after third dose, n (%)	68 (99%)	47 (100%)
3 months after third dose, n (%)	68 (99%)	45 (96%)
6 months after third dose, n (%)	57 (83%)	44 (94%)
<b>Post-vaccination SARS-CoV-2 infections, n (%)</b>	<b>30 (43%)</b>	<b>8 (17%)</b>